Soluble CD14 levels in plasma and breastmilk of Malawian HIV+ women: Lack of association with morbidity and mortality in their exposed infants

Silvia Baroncelli, Clementina M. Galluzzo, Giuseppe Liotta, Mauro Andreotti, Fausto Ciccacci, Sandro Mancinelli, Victor T. Tolno, Jane Gondwe, Roberta Amici, Maria C. Marazzi, Stefano Vella, Marina Giuliano, Leonardo Palombi, Lucia Palmisano

Research output: Contribution to journalArticle

Abstract

Problem: Data on soluble CD14 (sCD14) during pregnancy and lactation are scarce. We assessed the levels of sCD14 in plasma and breastmilk of Malawian HIV-positive women and evaluated the possible association with morbidity and mortality in the HIV-exposed children. Method of study: One hundred and forty-nine mother/child pairs were studied. Women received antiretroviral therapy from 26 weeks of gestation to at least 6 months of exclusive breastfeeding. sCD14 concentrations were determined using an enzyme-linked immunosorbent assay. Results: sCD14 levels measured at 26 weeks of pregnancy (median: 1418 ng/mL, IQR: 1086-1757) were inversely correlated to maternal CD4+ cell count (r = −.283, P =.001) and to neonatal birthweight (r = −.233, P =.008). At 6 months, sCD14 plasma levels were significantly higher compared to baseline (1993 ng/mL, IQR: 1482-2604, P <.001), and breastmilk sCD14 levels (7668 ng/mL, IQR: 5495-10207) were 4-fold higher than in plasma (although the concentrations in the two compartments were not correlated). No association was found between sCD14 levels in plasma or breastmilk and morbidity or mortality in children. Conclusion: Higher sCD14 levels in HIV-positive women were associated with a more compromised maternal immunological status and to a lower neonatal birthweight, but not to poorer clinical outcomes in the HIV-exposed children.

Original languageEnglish
Article numbere12812
JournalAmerican Journal of Reproductive Immunology
Volume79
Issue number3
DOIs
Publication statusPublished - Mar 1 2018

Fingerprint

HIV
Morbidity
Mortality
Mothers
Pregnancy
Child Mortality
CD4 Lymphocyte Count
Breast Feeding
Lactation
Enzyme-Linked Immunosorbent Assay
Therapeutics

Keywords

  • birthweight
  • HIV
  • Malawi
  • pregnancy
  • soluble CD14

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology
  • Reproductive Medicine
  • Obstetrics and Gynaecology

Cite this

Soluble CD14 levels in plasma and breastmilk of Malawian HIV+ women : Lack of association with morbidity and mortality in their exposed infants. / Baroncelli, Silvia; Galluzzo, Clementina M.; Liotta, Giuseppe; Andreotti, Mauro; Ciccacci, Fausto; Mancinelli, Sandro; Tolno, Victor T.; Gondwe, Jane; Amici, Roberta; Marazzi, Maria C.; Vella, Stefano; Giuliano, Marina; Palombi, Leonardo; Palmisano, Lucia.

In: American Journal of Reproductive Immunology, Vol. 79, No. 3, e12812, 01.03.2018.

Research output: Contribution to journalArticle

@article{0dc4635b004440719c95d3ce33a2271d,
title = "Soluble CD14 levels in plasma and breastmilk of Malawian HIV+ women: Lack of association with morbidity and mortality in their exposed infants",
abstract = "Problem: Data on soluble CD14 (sCD14) during pregnancy and lactation are scarce. We assessed the levels of sCD14 in plasma and breastmilk of Malawian HIV-positive women and evaluated the possible association with morbidity and mortality in the HIV-exposed children. Method of study: One hundred and forty-nine mother/child pairs were studied. Women received antiretroviral therapy from 26 weeks of gestation to at least 6 months of exclusive breastfeeding. sCD14 concentrations were determined using an enzyme-linked immunosorbent assay. Results: sCD14 levels measured at 26 weeks of pregnancy (median: 1418 ng/mL, IQR: 1086-1757) were inversely correlated to maternal CD4+ cell count (r = −.283, P =.001) and to neonatal birthweight (r = −.233, P =.008). At 6 months, sCD14 plasma levels were significantly higher compared to baseline (1993 ng/mL, IQR: 1482-2604, P <.001), and breastmilk sCD14 levels (7668 ng/mL, IQR: 5495-10207) were 4-fold higher than in plasma (although the concentrations in the two compartments were not correlated). No association was found between sCD14 levels in plasma or breastmilk and morbidity or mortality in children. Conclusion: Higher sCD14 levels in HIV-positive women were associated with a more compromised maternal immunological status and to a lower neonatal birthweight, but not to poorer clinical outcomes in the HIV-exposed children.",
keywords = "birthweight, HIV, Malawi, pregnancy, soluble CD14",
author = "Silvia Baroncelli and Galluzzo, {Clementina M.} and Giuseppe Liotta and Mauro Andreotti and Fausto Ciccacci and Sandro Mancinelli and Tolno, {Victor T.} and Jane Gondwe and Roberta Amici and Marazzi, {Maria C.} and Stefano Vella and Marina Giuliano and Leonardo Palombi and Lucia Palmisano",
year = "2018",
month = "3",
day = "1",
doi = "10.1111/aji.12812",
language = "English",
volume = "79",
journal = "American Journal of Reproductive Immunology and Microbiology",
issn = "1046-7408",
publisher = "Wiley-Blackwell",
number = "3",

}

TY - JOUR

T1 - Soluble CD14 levels in plasma and breastmilk of Malawian HIV+ women

T2 - Lack of association with morbidity and mortality in their exposed infants

AU - Baroncelli, Silvia

AU - Galluzzo, Clementina M.

AU - Liotta, Giuseppe

AU - Andreotti, Mauro

AU - Ciccacci, Fausto

AU - Mancinelli, Sandro

AU - Tolno, Victor T.

AU - Gondwe, Jane

AU - Amici, Roberta

AU - Marazzi, Maria C.

AU - Vella, Stefano

AU - Giuliano, Marina

AU - Palombi, Leonardo

AU - Palmisano, Lucia

PY - 2018/3/1

Y1 - 2018/3/1

N2 - Problem: Data on soluble CD14 (sCD14) during pregnancy and lactation are scarce. We assessed the levels of sCD14 in plasma and breastmilk of Malawian HIV-positive women and evaluated the possible association with morbidity and mortality in the HIV-exposed children. Method of study: One hundred and forty-nine mother/child pairs were studied. Women received antiretroviral therapy from 26 weeks of gestation to at least 6 months of exclusive breastfeeding. sCD14 concentrations were determined using an enzyme-linked immunosorbent assay. Results: sCD14 levels measured at 26 weeks of pregnancy (median: 1418 ng/mL, IQR: 1086-1757) were inversely correlated to maternal CD4+ cell count (r = −.283, P =.001) and to neonatal birthweight (r = −.233, P =.008). At 6 months, sCD14 plasma levels were significantly higher compared to baseline (1993 ng/mL, IQR: 1482-2604, P <.001), and breastmilk sCD14 levels (7668 ng/mL, IQR: 5495-10207) were 4-fold higher than in plasma (although the concentrations in the two compartments were not correlated). No association was found between sCD14 levels in plasma or breastmilk and morbidity or mortality in children. Conclusion: Higher sCD14 levels in HIV-positive women were associated with a more compromised maternal immunological status and to a lower neonatal birthweight, but not to poorer clinical outcomes in the HIV-exposed children.

AB - Problem: Data on soluble CD14 (sCD14) during pregnancy and lactation are scarce. We assessed the levels of sCD14 in plasma and breastmilk of Malawian HIV-positive women and evaluated the possible association with morbidity and mortality in the HIV-exposed children. Method of study: One hundred and forty-nine mother/child pairs were studied. Women received antiretroviral therapy from 26 weeks of gestation to at least 6 months of exclusive breastfeeding. sCD14 concentrations were determined using an enzyme-linked immunosorbent assay. Results: sCD14 levels measured at 26 weeks of pregnancy (median: 1418 ng/mL, IQR: 1086-1757) were inversely correlated to maternal CD4+ cell count (r = −.283, P =.001) and to neonatal birthweight (r = −.233, P =.008). At 6 months, sCD14 plasma levels were significantly higher compared to baseline (1993 ng/mL, IQR: 1482-2604, P <.001), and breastmilk sCD14 levels (7668 ng/mL, IQR: 5495-10207) were 4-fold higher than in plasma (although the concentrations in the two compartments were not correlated). No association was found between sCD14 levels in plasma or breastmilk and morbidity or mortality in children. Conclusion: Higher sCD14 levels in HIV-positive women were associated with a more compromised maternal immunological status and to a lower neonatal birthweight, but not to poorer clinical outcomes in the HIV-exposed children.

KW - birthweight

KW - HIV

KW - Malawi

KW - pregnancy

KW - soluble CD14

UR - http://www.scopus.com/inward/record.url?scp=85040567766&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85040567766&partnerID=8YFLogxK

U2 - 10.1111/aji.12812

DO - 10.1111/aji.12812

M3 - Article

C2 - 29323435

AN - SCOPUS:85040567766

VL - 79

JO - American Journal of Reproductive Immunology and Microbiology

JF - American Journal of Reproductive Immunology and Microbiology

SN - 1046-7408

IS - 3

M1 - e12812

ER -